PE20120817A1 - Peptidos tau antigenicos y usos de los mismos - Google Patents

Peptidos tau antigenicos y usos de los mismos

Info

Publication number
PE20120817A1
PE20120817A1 PE2012000116A PE2012000116A PE20120817A1 PE 20120817 A1 PE20120817 A1 PE 20120817A1 PE 2012000116 A PE2012000116 A PE 2012000116A PE 2012000116 A PE2012000116 A PE 2012000116A PE 20120817 A1 PE20120817 A1 PE 20120817A1
Authority
PE
Peru
Prior art keywords
sequence
seq
amino acids
vlp
immunogen
Prior art date
Application number
PE2012000116A
Other languages
English (en)
Spanish (es)
Inventor
George Joseph Smith Iii
Kenneth Nelson Wills
Jeff Xianchao Zhu
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of PE20120817A1 publication Critical patent/PE20120817A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2012000116A 2009-07-30 2010-07-20 Peptidos tau antigenicos y usos de los mismos PE20120817A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30

Publications (1)

Publication Number Publication Date
PE20120817A1 true PE20120817A1 (es) 2012-07-07

Family

ID=42941871

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000116A PE20120817A1 (es) 2009-07-30 2010-07-20 Peptidos tau antigenicos y usos de los mismos

Country Status (17)

Country Link
US (1) US20110177109A1 (enEXAMPLES)
EP (1) EP2459214A1 (enEXAMPLES)
JP (1) JP2013500326A (enEXAMPLES)
KR (2) KR20130127547A (enEXAMPLES)
CN (1) CN102596236B (enEXAMPLES)
AR (1) AR078085A1 (enEXAMPLES)
AU (1) AU2010277254B2 (enEXAMPLES)
CA (1) CA2768346A1 (enEXAMPLES)
CO (1) CO6612199A2 (enEXAMPLES)
IN (1) IN2012DN00446A (enEXAMPLES)
MX (1) MX2012001194A (enEXAMPLES)
NZ (2) NZ618391A (enEXAMPLES)
PE (1) PE20120817A1 (enEXAMPLES)
RU (2) RU2518291C2 (enEXAMPLES)
SG (1) SG177637A1 (enEXAMPLES)
TW (2) TW201436804A (enEXAMPLES)
WO (1) WO2011013034A1 (enEXAMPLES)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
EP2670434B1 (en) 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
CN104080806B (zh) 2011-10-07 2018-01-19 Ac免疫有限公司 识别Tau的磷酸化特异抗体
CA2869438C (en) 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
NZ703423A (en) * 2012-07-03 2018-02-23 Univ Washington Antibodies to tau
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP6568514B2 (ja) 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
EP3027205A4 (en) * 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
JP6913078B2 (ja) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
MA50465A (fr) 2017-10-25 2020-09-02 Ac Immune Sa Compositions de peptides tau phosphorylés et leurs utilisations
CN119409835A (zh) * 2017-10-27 2025-02-11 联脑科学公司 Tau肽免疫原构建体
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
CN108314737B (zh) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 一种重组蛋白及其制备方法和应用
CN110548135B (zh) * 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
CA3148562A1 (en) 2018-10-07 2020-04-16 Neil R. Cashman Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
BR112021015501A2 (pt) * 2019-02-08 2021-10-19 Prothena Biosciences Limited Anticorpos que reconhecem tau
KR20210125048A (ko) 2019-02-08 2021-10-15 에이씨 이뮨 에스.에이. 인산화 타우 펩티드 백신의 안전한 투여 방법
WO2020186091A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
JP7617852B2 (ja) 2019-04-24 2025-01-20 ヤンセン ファーマシューティカルズ，インコーポレーテッド タウワクチンの異種投与
WO2020236969A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
KR20220034733A (ko) * 2019-05-27 2022-03-18 더 유니버시티 오브 브리티쉬 콜롬비아 타우의 입체형태-특이적 에피토프, 이에 대한 항체 및 이와 관련된 방법
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
AU2021321206A1 (en) * 2020-08-07 2023-03-09 Othair Prothena Limited Tau vaccine for the treatment of alzheimer's disease
EP4212172A4 (en) * 2020-09-08 2024-10-16 Osaka University Immunogenic composition targeting phosphorylated tau protein
PE20241207A1 (es) * 2021-09-08 2024-06-06 Biocad Joint Stock Co Anticuerpo quimerico, biespecifico, bivalente que comprende un heterodimero basado en cmh o proteinas similares a cmh
CN118613496A (zh) * 2021-09-29 2024-09-06 杨森制药公司 安全施用Tau磷酸肽缀合物的方法
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
JP2547714B2 (ja) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (de) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Insektizid wirksames mittel zur bekaempfung von textilschaedlingen
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU9052091A (en) 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
EP0911398B1 (en) * 1991-12-06 2008-06-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0817854A2 (en) 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
CA2283557A1 (en) 1997-03-10 1998-09-17 Heather L. Davis Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
NZ506245A (en) 1998-02-12 2003-08-29 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
ES2258869T3 (es) 1998-10-21 2006-09-01 The United States Government As Represented By The Department Of Health And Human Services Particulas similares a virus para la induccion de autoanticuerpos.
CA2349505A1 (en) 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
CN1193791C (zh) 1998-11-30 2005-03-23 希托斯生物技术股份公司 抗原的有序分子呈递,制备及使用的方法
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
AR022964A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
PL203951B1 (pl) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
BR0014282A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Vacinas
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
DK1268530T3 (da) 2000-04-07 2006-11-13 Univ Leeds Hepatitis B-kerneantigen-fusionsproteiner
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
PT1294893E (pt) 2000-06-22 2006-08-31 Ucb Pharma Ltd Modificacao do antigenio nuclear de hepatite b
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2003213168A1 (en) 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
EP1532167B1 (en) 2002-07-17 2012-01-25 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
EP2338510A1 (en) * 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
NZ540620A (en) 2002-12-10 2009-03-31 Lorantis Ltd Stabilized immunogenic HBc chimer particles
WO2005058940A2 (en) * 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
RU2007117752A (ru) * 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EP1844788B1 (en) * 2006-04-13 2010-07-14 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. HER-2/neu multi-peptide vaccine
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
FR3058624B1 (fr) 2016-11-15 2018-12-07 L'oreal Brosse pour l'application d'un produit sur les cils et/ou les sourcils

Also Published As

Publication number Publication date
TW201106968A (en) 2011-03-01
WO2011013034A1 (en) 2011-02-03
RU2014112002A (ru) 2015-10-10
NZ618391A (en) 2015-07-31
TWI461209B (zh) 2014-11-21
WO2011013034A4 (en) 2011-04-28
CO6612199A2 (es) 2013-02-01
TW201436804A (zh) 2014-10-01
CA2768346A1 (en) 2011-02-03
SG177637A1 (en) 2012-03-29
RU2518291C2 (ru) 2014-06-10
US20110177109A1 (en) 2011-07-21
KR20130127547A (ko) 2013-11-22
MX2012001194A (es) 2012-03-07
EP2459214A1 (en) 2012-06-06
AR078085A1 (es) 2011-10-12
RU2012102701A (ru) 2013-09-10
CN102596236B (zh) 2015-06-24
CN102596236A (zh) 2012-07-18
JP2013500326A (ja) 2013-01-07
AU2010277254B2 (en) 2015-05-07
NZ598356A (en) 2014-06-27
KR20120049900A (ko) 2012-05-17
IN2012DN00446A (enEXAMPLES) 2015-05-15
AU2010277254A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
PE20120817A1 (es) Peptidos tau antigenicos y usos de los mismos
PE20110891A1 (es) Vacuna de peptido ch3 de ige
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
PE20161560A1 (es) Vacuna de pcsk9
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
HRP20161710T1 (hr) Identifikacija, optimizacija i uporaba kriptičkih hla-a24 etiopa za imunoterapiju
PE20081723A1 (es) Vacuna contra el papilomavirus
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
RU2492182C3 (ru) ГИДРОФОБНЫЕ, МОДИФИЦИРОВАННЫЕ, ПОЛУЧЕННЫЕ ИЗ preS ВИРУСА ГЕПАТИТА В (HBV) ПЕПТИДЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОНИКНОВЕНИЯ HBV И HDV
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
JP2014502156A5 (enEXAMPLES)
ES2454773T3 (es) Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN
JP2015501840A5 (enEXAMPLES)
EP2403871A4 (en) FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES
RU2017135038A (ru) Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток
JP2012525410A5 (enEXAMPLES)
JP2014507146A5 (enEXAMPLES)
JP2012102105A5 (enEXAMPLES)
RU2015140603A (ru) Вакцины на основе нуклеопротеина вируса гриппа
JP2016520534A5 (enEXAMPLES)
Gunay et al. Peptide aggregation induced immunogenic rupture (PAIIR)
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
MX2015005056A (es) Antigenos ampliamente reactivos computacionalmente optimizados para influenza h1n1.
JP2018501258A5 (enEXAMPLES)

Legal Events

Date Code Title Description
FC Refusal